Showa University Hospital

Tokyo 142-8666

1 studies enrolling now · 12 studies all time

What they study most

Asthma, Breast Cancer, CRT-D Cardiac Resynchronization Therapy Defibrillator, Chronic Coronary Insufficiency, Early Breast Cancer, Implantable Cardioverter Defibrillators, Locally Advanced or Unresectable Metastatic Breast Cancer, Metastatic HER2-positive Breast Cancer, Non ST Elevation Myocardial Infarction, PD-L1 Negative, PD-L1 Positive, Stage IV Breast Cancer

Studies at this site

• A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer — Recruiting now
• A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication — Completed
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Running, not enrolling
• Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer — Running, not enrolling
• DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] — Running, not enrolling
• Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy — Running, not enrolling
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Running, not enrolling
• A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer — Completed
• Pullback Pressure Gradient (PPG) Global Registry — Running, not enrolling
• An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus — Completed
• LONGEVITY Study. Evaluation of the Device and Battery Longevity of Boston Scientific Market-released ICD and CRT-D Devices — Completed
• Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis — Completed